[Federal Register Volume 81, Number 96 (Wednesday, May 18, 2016)]
[Notices]
[Pages 31250-31251]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-11661]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Start-up Exclusive License: Development of 
Virus Like Particles for the Treatment of Breast Cancer, Lung Cancer, 
Melanoma, Pancreatic Cancer, and Hepatocellular Cancer

AGENCY: National Institutes Of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 
part 404.7, that the National Cancer Institute, National Institutes of 
Health, Department of Health and Human Services, is contemplating the 
grant of a Start-Up Exclusive Patent License to practice the inventions 
embodied in the following patent applications to Chimeron Bio 
Corporation, a company incorporated under the laws of Delaware and 
having an office in Philadelphia, PA.
    Intellectual Property: U.S. Provisional Patent Application No.: 61/
615,687 Entitled ``Delivery of Packaged RNA in Mammalian Cells'' HHS 
Ref. No.: E-264-2011/0-US-01 Filed March 26, 2012; International Patent 
Application No.: PCT/US2013/031876 Entitled ``Delivery of Packaged RNA 
in Mammalian Cells'' HHS Ref. No.: E-264-2011/0-PCT-02 Filed March 15, 
2013; Australian Patent Application No.: 2013-240248 Entitled 
``Delivery of Packaged RNA in Mammalian Cells'' HHS Ref. No.: E-264-
2011/0-AU-03 Filed October 17, 2014; European Patent Application No.: 
13712661.1 Entitled ``Delivery of Packaged RNA in Mammalian Cells'' HHS 
Ref. No.: E-264-2011/0-EP-04 Filed October 24, 2014; Japanese Patent 
Application No.: 2015-503322 entitled ``Delivery of Packaged RNA in 
Mammalian Cells'' HHS Ref. No.: E-264-2011/0-JP-05 Filed September 25, 
2014; U.S. Patent Application No.: 14/388,441 Entitled Delivery of 
Packaged RNA in Mammalian Cells'' HHS Ref. No.: E-264-2011/0-US-06 
Filed September 26, 2014; U.S. Provisional Patent Application No.: 61/
916,394 Entitled ``Cancer Immunotherapy: Delivery HLA-11 using VLP-
Replicon'' HHS Ref. No.: E-050-2014/0-US-01 Filed December 16, 2013; 
International Patent Application No.: PCT/US2014/070552 Entitled 
``Cancer Immunotherapy: Delivery HLA-11 using VLP-Replicon'' HHS Ref. 
No.: E-050-2014/0-PCT-02 Filed December 16, 2014;
    The patent rights to these inventions have been assigned to the 
Government of the United States of America.
    The prospective exclusive start-up licensed territory may be 
worldwide and the field of use may be limited to: ``Use of virus like 
particles comprising MHCII and CD80 for the treatment of breast cancer, 
lung cancer, melanoma, pancreatic cancer, and hepatocellular cancer.''

DATES: Only written comments and/or applications for a license which 
are received by the NCI Technology Transfer Center on or before June 2, 
2016 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
and comments relating to the contemplated exclusive license should be 
directed to: Lauren Nguyen-Antczak, Ph.D., J.D., Sr. Licensing and 
Patenting Manager, Technology Transfer Center, National Cancer 
Institute, 8490 Progress Drive, Riverside 5, Suite 400, Frederick, MD 
21701; Telephone: (301) 624-8752; Email: [email protected].

SUPPLEMENTARY INFORMATION: The invention is directed to virus-like 
particles (``VLPs'') that serve to induce transgene expression of at 
least one recombinant protein of interest in specific, targeted cells. 
This technology can be used to treat a variety of diseases, depending 
on the cell type to be targeted. Preferably, invention VLPs may be used 
to treat tumor bearing cancers, including breast cancer, lung cancer, 
melanoma, pancreatic cancer, and hepatocellular cancer.
    The prospective Start-Up Exclusive Patent License, which will be 
royalty bearing, is being considered under the small business 
initiative launched on 1 October 2011 and will comply with the terms 
and conditions of 35 U.S.C. 209 and 37 CFR part 404.7. The prospective 
Start-Up Exclusive Patent License may be granted unless the NIH 
receives written evidence and argument, within fifteen (15) days from 
the date of this published notice, that establishes that the grant of 
the license would not be consistent with the requirements of 35 U.S.C. 
209 and 37 CFR part 404.7.
    Complete applications for a license in the field of use filed in 
response to this notice will be treated as objections to the grant of 
the contemplated exclusive start-up license. Comments and objections 
submitted to this notice will not be made available for public 
inspection and, to the extent permitted by law, will not be released 
under the Freedom of Information Act, 5 U.S.C. 552.


[[Page 31251]]


    Dated: May 12, 2016.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2016-11661 Filed 5-17-16; 8:45 am]
 BILLING CODE 4140-01-P